Statiner, som er substrater af CYP3A, forventes derfor ikke at have en virkning på prasugrels farmakokinetik eller dets hæmning af blodpladeaggregering. ###>Therefore, statins that are substrates of CYP3A are not anticipated to have an effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.